Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 9/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26446044 | 0.89 | TLR4 (0.61) | TLR4HPGDALDH1A1RECQLCA1 | |
| SCHEMBL26428772 | 0.87 | TLR4 (0.58) | TLR4HPGDALDH1A1RECQLCA1 | |
| SCHEMBL23417930 | 0.84 | TLR4 (0.62) | TLR4HPGDALDH1A1GAA | |
| SCHEMBL23417853 | 0.83 | TLR4 (0.51) | TLR4 | |
| SCHEMBL23417821 | 0.83 | TLR4 (0.52) | TLR4RAB9A | |
| SCHEMBL872983 | 0.82 | TLR4 (0.70) | TLR4HPGDALDH1A1RECQLCA1 | |
| SCHEMBL873524 | 0.81 | TLR4 (0.68) | TLR4HPGDALDH1A1RECQLCA1 | |
| SCHEMBL26422997 | 0.81 | TLR4 (0.51) | TLR4 | |
| SCHEMBL871345 | 0.81 | TLR4 (0.71) | TLR4HPGDALDH1A1RECQLCA1 | |
| SCHEMBL872345 | 0.81 | TLR4 (0.76) | TLR4HPGDRECQLMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | TLR4 3806/4885HPGD 4378/4885ALDH1A1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.